The complete list of substances being removed from Category 2 is as follows: BPC-157 Cathelicidin LL-37 Dihexa Acetate Emideltide (DSIP) Epitalon GHK-Cu (for injectable routes of administration) KPV Mechano Growth Factor, Pegylated (PEG-MGF) Melanotan II MOTs-C Semax (heptapeptide) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) Of these, the substances not scheduled for consideration at the upcoming meeting in July (Cathelicidin LL-37, Dihexa Acetate, GHK-Cu (injectable routes of administration), Mechano Growth Factor Pegylated (PEG-MGF), and Melanotan II) are slated for separate PCAC consultation before the end of February 2027
None of these interactions has been quantified in human pharmacokinetic-pharmacodynamic studies
Archived from the original on April 12, 2018
Pharmacological methods of pain management: narrative review of medication used
[DOI] [PubMed] [Google Scholar] 11.Kollias N, Baqer AH
In a healthy, unstressed cell, more than 90% of total glutathione exists in its active, "reduced" state, known as GSH
